La formation du complexe de fusion qui précède la fusion est essentielle à l’infection de la cellule-cible par le VIH-1. L’inhibition de la formation de ce complexe de fusion peut empêcher l’infection et représenter un moyen de traitement antirétroviral. Plusieurs équipes ont essayé de produire des anticorps neutralisants par immunisation de souris ou de lapins avec des peptides linéaires non conformationnels, mais sans résultat. L’élaboration d’une lignée de cellules eucaryotes exprimant la structure HR1-PID-HR2 TM viral nous a permis de le faire. Cette lignée est un outil susceptible d’engendrer des anticorps monoclonaux (mAb). Trois mAbs contre le complexe de fusion de la région gp41 ont été produits chez la souris. L’activité neutralisa...
Monoclonal antibody (MAb) ICR41.1i (rat IgG2a) is specific for a conformation-dependent epitope of h...
Anti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broaden...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Envelope glycoprotein is the primary target for human immunodeficiency virus (HIV) vaccine design. T...
La formation du complexe de fusion qui précède la fusion est essentielle à l infection de la cellule...
Human immunodeficiency virus-1 (HIV-1) infects cells by membrane fusion that is mediated by the enve...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Background The narrow spectrum of HIV-specific neutralizing antibodies points to the need for new im...
The HIV-1 pandemic emerged in 1981 and has devastated global health for over four decades. It has re...
La difficulté à induire des anticorps capables de neutraliser (anticorps neutralisants, AcN) la très...
Development of chimeric humanized monoclonal antibodies against HIV-1 Dalila Astone, Pierpaolo Ra...
The development of neutralizing antibodies against HIV-1 is of pivotal importance for the developmen...
Neutralisation by antibody is, for a number of viruses, an in vitro correlate for protection in vivo...
The narrow spectrum of HIV-specific neutralizing anti- bodies points to the need for new immunogens ...
Degree awarded: Ph.D. Biology. The Catholic University of AmericaThe HIV-1 envelope spike is a trime...
Monoclonal antibody (MAb) ICR41.1i (rat IgG2a) is specific for a conformation-dependent epitope of h...
Anti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broaden...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...
Envelope glycoprotein is the primary target for human immunodeficiency virus (HIV) vaccine design. T...
La formation du complexe de fusion qui précède la fusion est essentielle à l infection de la cellule...
Human immunodeficiency virus-1 (HIV-1) infects cells by membrane fusion that is mediated by the enve...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Background The narrow spectrum of HIV-specific neutralizing antibodies points to the need for new im...
The HIV-1 pandemic emerged in 1981 and has devastated global health for over four decades. It has re...
La difficulté à induire des anticorps capables de neutraliser (anticorps neutralisants, AcN) la très...
Development of chimeric humanized monoclonal antibodies against HIV-1 Dalila Astone, Pierpaolo Ra...
The development of neutralizing antibodies against HIV-1 is of pivotal importance for the developmen...
Neutralisation by antibody is, for a number of viruses, an in vitro correlate for protection in vivo...
The narrow spectrum of HIV-specific neutralizing anti- bodies points to the need for new immunogens ...
Degree awarded: Ph.D. Biology. The Catholic University of AmericaThe HIV-1 envelope spike is a trime...
Monoclonal antibody (MAb) ICR41.1i (rat IgG2a) is specific for a conformation-dependent epitope of h...
Anti-human immunodeficiency virus type-1 (anti-HIV-1) neutralizing monoclonal antibodies are broaden...
Broadly neutralizing antibodies (bNAbs) have remarkable breadth and potency against most HIV-1 subty...